Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114816 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL21009583 | 0.79 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL7952831 | 0.79 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL32346286 | 0.79 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL1579049 | 0.79 | LMNA (0.57) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL22268391 | 0.79 | CFTR (0.44) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| Hydrochloric Acid SCHEMBL5448253 | 0.78 | LMNA (0.55) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL13114805 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAL3MBTL1GAAADRB3 | |
| SCHEMBL14168820 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL25233552 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAL3MBTL1GAACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | SMN1; SMN2 2751/4885LMNA 1916/4885L3MBTL1 4099/4885 |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2610/4885LMNA 4584/4885L3MBTL1 4369/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | SMN1; SMN2 3157/4885LMNA 2295/4885L3MBTL1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.